Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia.
Over the last decade, management of benign prostatic hyperplasia (BPH) has changed with a substantial decrease in the use of transurethral prostatectomy (TURP) and a simultaneous increase in the use of medical therapy and minimally invasive surgical therapy (MIST). The goal of management of this chronic progressive condition is not only to provide relief of lower urinary tract symptoms (LUTS) but also to reduce the lifetime risk of adverse outcomes. Recent clinical evidence has demonstrated a clear role for medical therapy, particularly with 5-alpha-reductase inhibitors (5ARIs) either alone or in combination with alpha-blockers, to reduce the risk of acute urinary retention and need for surgery and provide symptom relief. Clinical data on MISTs also indicate a more pronounced short-term effect; however, the long-term durability of these therapies remains uncertain. Minimally invasive surgical therapies confer treatment benefits in a single 1-h treatment session under local anesthesia. Recovery times and adverse events are improved compared with TURP, but issues such as hematuria, prolonged catheterization, urinary tract infection and retreatment remain commonly reported issues. Today, urologists are faced with the challenge of identifying the most appropriate treatment option for the long-term management of BPH. The initial choice for any given patient will depend on his presenting circumstances and the influence of treatment risks on these circumstances. Providing patients with informed treatment decisions is a key element of management.
Harkaway
R C
RC
Residency Training Urology, Albert Einstein Medical Center, Philadelphia, PA 19141, USA. harks99@aol.com
Issa
M M
MM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000379:methods* / Q000639:trends; D008954:Models, Biological; D011230:Precancerous Conditions / Q000188:drug therapy / Q000601:surgery; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery*; D014481:United States
D000970:Antineoplastic Agents